drugset
drugset / Trial / NCT07613684

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

NCT07613684 ↗

Phase 1 Completed 100 enrolled Epirium Bio Inc.
RandomizedSequentialDouble-blindTreatment

Summary

The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose \[SAD\] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose \[MAD\] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (\> 65 to ≤75 years of age) healthy adult subjects.

Timeline

Start
2024-12-20
Primary completion
2025-10-09
Completion
2025-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MF-300 Unknown 75 mg Oral
Subject MF-300 Unknown 125 mg Oral
Subject MF-300 Unknown 200 mg Oral
Subject MF-300 Unknown 250 mg Oral
Subject MF-300 Unknown 500 mg Oral
Subject MF-300 Unknown 800 mg Oral

Indications

No indication recorded.